Hims & Hers Health, Inc. $HIMS Shares Sold by Abacus FCF Advisors LLC

Key Points

• Abacus FCF Advisors LLC has significantly reduced its holdings in Hims & Hers Health, selling 62,147 shares, which represents a 52.6% decrease in their position during the second quarter.
• Analysts have mixed views on Hims & Hers Health, with ratings ranging from "buy" to "sell", and a consensus price target of approximately $38.92.
• Hims & Hers Health reported a quarterly earnings miss, with earnings per share of $0.17 compared to analysts' expectations of $0.18, despite a revenue increase of 72.6% year-over-year.

Abacus FCF Advisors LLC decreased its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 52.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 55,943 shares of the company's stock after selling 62,147 shares during the quarter. Abacus FCF Advisors LLC's holdings in Hims & Hers Health were worth $2,789,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in HIMS. Geneos Wealth Management Inc. purchased a new position in Hims & Hers Health during the first quarter valued at $30,000. UMB Bank n.a. raised its position in Hims & Hers Health by 247.5% in the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock valued at $39,000 after purchasing an additional 933 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Hims & Hers Health during the 1st quarter worth $41,000. Larson Financial Group LLC lifted its stake in shares of Hims & Hers Health by 47.7% in the 1st quarter. Larson Financial Group LLC now owns 1,419 shares of the company's stock worth $42,000 after acquiring an additional 458 shares during the period. Finally, Webster Bank N. A. increased its holdings in shares of Hims & Hers Health by 229.1% in the 2nd quarter. Webster Bank N. A. now owns 905 shares of the company's stock valued at $45,000 after purchasing an additional 630 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

Analyst Upgrades and Downgrades

HIMS has been the subject of several recent research reports. Truist Financial dropped their target price on shares of Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating for the company in a report on Monday, August 18th. Wall Street Zen lowered shares of Hims & Hers Health from a "buy" rating to a "hold" rating in a research note on Monday, July 28th. Zacks Research lowered shares of Hims & Hers Health from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 19th. Citigroup reaffirmed a "sell" rating on shares of Hims & Hers Health in a research report on Monday, June 23rd. Finally, Morgan Stanley restated an "equal weight" rating and issued a $40.00 price objective on shares of Hims & Hers Health in a report on Wednesday, June 11th. Two investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of "Reduce" and an average target price of $38.92.

Insider Buying and Selling

In other news, insider Michael Chi sold 13,750 shares of the company's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $56.00, for a total transaction of $770,000.00. Following the transaction, the insider directly owned 278,654 shares of the company's stock, valued at approximately $15,604,624. This represents a 4.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Andrew Dudum sold 660,000 shares of the company's stock in a transaction on Thursday, August 7th. The shares were sold at an average price of $50.58, for a total value of $33,382,800.00. Following the completion of the transaction, the chief executive officer directly owned 2,214,769 shares in the company, valued at approximately $112,023,016.02. The trade was a 22.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,511,978 shares of company stock worth $76,944,116. Insiders own 17.71% of the company's stock.

Hims & Hers Health Price Performance

Shares of HIMS traded down $1.85 during midday trading on Tuesday, reaching $55.86. The stock had a trading volume of 17,209,102 shares, compared to its average volume of 33,039,504. Hims & Hers Health, Inc. has a 12-month low of $16.05 and a 12-month high of $72.98. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72. The company's 50-day moving average is $50.83 and its 200 day moving average is $45.92. The company has a market capitalization of $12.62 billion, a price-to-earnings ratio of 69.62, a price-to-earnings-growth ratio of 3.91 and a beta of 2.14.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported $0.17 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The firm had revenue of $544.83 million during the quarter, compared to the consensus estimate of $550.06 million. During the same period in the prior year, the company posted $0.06 EPS. The firm's revenue was up 72.6% on a year-over-year basis. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.